JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed or refractory B cell lymphoma / leukemia. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY231 injection in the treatment of relapsed or refractory B cell lymphoma / leukemia.

Trial Details

NCT ID
NCT06678282
Phase
NA
Sponsor
Shenzhen Genocury Biotech Co., Ltd.
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • JY231 Injection
Locations (sample)
  • Zhenzhou, Henan, China

Key Eligibility Criteria

  • Subject voluntarily sign informed consent and are willing and able to comply with all trial requirements;
  • Age is 18-75 years old and gender is not limited;
  • Malignancy cells in bone marrow or peripheral blood are Cluster of Differentiation 19 - positive(CD19+) detected by flow cytometric analysis;
  • Meet the clinical criteria for relapsed or refractory B-cell lymphoma, including: indolent lymphoma (iNHL), such as follicular lymphoma (FL) and ma…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →